Our ELP platform technology is a growth engine for additional medicines for cardiovascular diseases. It offers the benefits of extended half-life, enhanced usability and simple manufacturing.
Our proprietary technology platform is based on recombinant biopolymers called elastin-like polypeptides (ELPs), which comprise individual building blocks derived from a five-amino acid repeat motif found in the human protein elastin. This five-amino acid motif is repeated multiple times to form the ELP biopolymer.
Our ELP technology extends the circulating half-life of proteins and peptides and also provides a sustained-release mechanism, resulting in exposure of active molecules for periods of a week or longer from a single subcutaneous injection.
Our strategy is to apply our ELP technology to proteins and peptides with well-characterized therapeutic activities but suboptimal half-lives to improve their pharmacokinetics, enable their use as pharmaceutical products and allow for more convenient dosing regimens.
We use essential cookies to make our site work. These enable core functionality such as security and accessibility. Essential cookies are on by default. You can disable these by changing your browser settings, but this may affect how the website functions.
Google Analytics Cookies
We would like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. These cookies collect information in a way that does not directly identify anyone.